General Session: Anne Wojcicki, CEO and Co-Founder, 23andMe and Chrissy Farr, CNBC

Anne Wojcicki
1 follower
1 Video View·Mar 31, 2026
23andMe: What's Next For The Personal Genetics Pioneer: Tuesday, October 29, 2019
AI Generated·May contain errors
Please welcome Anne Wojcicki, CEO and co-founder of 23andMe,
who will be interviewed by CNBC reporter Chrissy Farr.
I am Chrissy Farr from CNBC. I'm a healthcare and technology reporter and I'm here with
Anne Wojcicki from 23andMe, who we're excited to talk to you guys about genomics. Are we the only
genomics panel at HLTH? So I think we are. Yeah. Yeah. Okay. So we got to, we got to own this
topic. We will. So you've had quite the year. I mean, everything from the Golden State Killer,
which was just a massive news story to, on the personal front, you just had a baby. I did.
Congratulations. Thank you. So talk to me about this year that you've had and, you know, looking
back at this kind of, what is your perspective now on the industry and how 23andMe fits in?
I think, you know, I think the Golden State Killer is, again, it's raised a lot of the
privacy concerns I think that people have had. And it's an interesting example of, you know,
something that we premeditated, like back in the early days of the company, it's actually part of
one of the things that we disclosed, this could happen one day. And so it's interesting to see
it's actually happening now. So privacy is definitely one of those things that I think
has become a hot topic for not just companies like 23andMe and the health sector, but also the
tech world and, you know, companies like Facebook and Google and like, and there's, again, there's
a bunch of New York Times articles today even about like, how is my data actually being used
and was it really consented in the right kind of way? So that's definitely a hot topic that I
think 23andMe really wants to be on top of. I think other things that happened with the
company is we always said, you know, when I look around the booths that we have here and I think
about, you know, what is going to define success for those companies, the hardest thing for all of
us is getting scale. Like there's a lot of great ideas out there in those booths, but it's really
hard to get eyeballs and it's hard to get scale. So when I think about the first 11 years of 23andMe,
it was really about building out the infrastructure of scale. So we have over 10 million customers,
over 80% of them have consented for research. I now feel like I have enough of a scale for the
company that we could actually try to make significant changes in, in, for our customers
and in healthcare. And if I think about our mission, the mission state of the company is
helping people access, understand, and benefit from the human genome. And the first decade was
really about access and understand the human genome. And I look at now, how is it that we are
actually going to help all of our customers benefit from the human genome? And you can't
really benefit without scale. So, you know, you've brought up privacy, which I think is, you know,
just a massive topic for the, for the company. And, you know, whenever I talk about 23andMe,
inevitably somebody will hit back and say, this is a company that is selling my data to Pharma.
So do you feel like your customers really understand what is happening to their
information when they're using a service like 23andMe? And is that like, is that still an
education that you see needing to happen? It's a huge priority for us to make sure that our
customers, when they opt in, and I should emphasize that word opt in, our customers are opting into
research or whatever, you know, if they're taking a survey or if they're opting into research or
individual level consent, it's a choice. And so we really want our customers to actually pause
and read it. And we've worked with the IRB to make sure that this is actually something
that is understandable for people. So we really try hard. And I think for those of you who are
customers, you can see it's not necessarily the easiest sign in process or even to buy the kit.
It takes time. And, you know, any normal tech company would say, you know, this is too onerous,
like this is we, you know, things we need to change. But we've always felt that was really
important for customers to understand exactly what they are getting and the opt in process.
So more often than not, what our customers ask is they actually want to see a difference in
healthcare. And I think, again, we're at a health meeting here. Health is like the universal
bond between all of us that we're all really frustrated with it. And people can relate. Like
if you have a family member who's sick or something, like we all want to help. And so part
of opting into research is this idea that you can do something. And I think one thing when I've
surveyed my customers and I talked to people, and again, even when I worked at places like NCI,
there's nothing more disheartening than knowing you have a terminal illness and you consented
for research and your sample is sitting in the lab and no one's doing anything. So more often
than not, our customers were coming to us and saying, just do something, like make progress.
And especially for people who have a terminal illness, they want to know, is there something
that can happen that's going to benefit them? Or is there something that we can do that's going to
help benefit their children? And so that's the lens that we're always thinking about. This is
what is it that we can do? And every time you're taking a survey, it says on the top,
are you opted in or are you not in research? And it always gives you the opportunity to opt out.
And I think it's a really key component of 23andMe that's very different than a lot of academic
research, is that you have that ability at any point in time to say, I no longer want to be
participating. So I may be one of the few folks out there that has read the terms and conditions
for 23andMe. I don't think most people do for almost anything, and that's totally fair, right?
And one of the things that you guys actually say is that you could potentially find out quite
shocking and life-changing things if you get a 23andMe test. And just in talking to people at
this conference, people have come up and said, I found out this crazy story about my father isn't
my father. I've got this family member I never knew I had. So what do you think about those
sorts of stories? I mean, you must hear them all the time.
It's where I actually say it. People come up to us in those early days. People would come up to
us and say, they're angry. I'm never going to do your test for this reason and that reason. I'd be
like, that's great. Don't do it. It's not for everybody. And the reality is that you do learn
things. There's things in your DNA, whether it's on the health side or the ancestry side or family
relationships, that might tell a different story than what you perceive of yourself.
And so it's really important for us that our customers actually pause when they buy the
product or when they're thinking about, like, am I opting into relative find or DNA relatives?
They pause and understand that, yes, they might learn something that is surprising for them.
So we actually, because we have so many of these stories now about people finding out that they
were children, like their father is not their father, they're a child of a sperm donor,
that they have siblings they didn't know about, we actually did launch a resources page
for our customers about how to handle this. Because we have, it's ironic because of the
FDA issues, we spent a lot of time focusing on the health side. But what I actually see is that
the ancestry side in some ways is more life changing for people because it really changes
their sense of identity. Yeah, I mean, I'm curious, just have you ever tried to quantify,
say, the percentage of people that are finding out, particularly a paternity surprise?
I mean, we don't have, I mean, we don't know stats on every single one of our customers about,
you know, whether or not they're their family, but we do, I mean, we have thousands of customer
stories. And in some ways, it's, you know, every, we have somebody who just collects stories every
single day. And she's like, there's once a day, where I sit back and I just say, holy cow,
like, that's an amazing story. And, you know, the reality is humans are really interesting.
And, and there's all kinds, you know, I always joke, I was like, people are really interesting,
and people also like sex. So there's, there's consequences to that. And there's all kinds
of interesting stories that have come out of it. So it's important for us that our customers are
aware when they are buying and when they're actually consenting into it, and that they
think about it. But it does, it does really change people. And oftentimes, like, again,
we get some amazing stories of people, you know, I'm actually one of the customers who's found a
story, like I found a first cousin. You know, it turns out that my uncle had a child he didn't
know about. And so like this, you know, poor guy, who's now a very close family friend, you know,
like thought he had no siblings. And now he, he has a lot of Hojiskies. Like,
there's a lot of us, it's interesting to bump into. But you know, it's, it's, it's been a
lovely experience. And I think that's part of my hope here is with services like DNA relatives,
and with the, you know, ancestry composition is it actually brings humanity closer together,
and that people start to find relationships that they never knew about before. And that people
realize, like, I had a perception of myself as being, you know, 100% something. And then I
realized I actually have DNA from all over the world. And I'm connected to all these people.
So you guys as a company have sort of wavered back and forth over the years on whether you will
stick to genotyping? Yeah, what you offer today, or get into more of a whole genome sequencing
product, which would be a lot more expensive. But in theory, you could find out a lot more about a
person's health based on you know, that richer and deeper sequence. So why, where are you with
that discussion now to sequence or not to sequence? So sequencing, sequencing is like the fancy toy
that a lot of people talk about. And I think there's a definitely there's a place in the
healthcare market for sequencing. The reality is that it's one to three, one to 5% of customers
find out that they have some kind of mutation. So for the for like a direct to consumer product,
that's not necessarily a very exciting experience for customers. If one to 5%, let's say you're
going to find something out. And also, I think there's a question is like, what's that right
place? You know, I think that's potentially, you know, there's still the issue of variants
of unknown significance, exactly how do you follow up on some of these mutations.
So we've stuck to the genotyping platform, in part because we also we see that, you know,
the price point for customers is in the genotyping, you know, affordability,
like customers really are between that $100 and $200 kind of price.
And a sequencing product could be
a sequencing product is to do a well, I mean, sequencing products can be much more expensive,
you know, certainly north of $500. So I think that there's two things like one,
there's a price component. And I think there's a question about, you know, customers aren't
necessarily running out to say, I want to know if I'm one of part of that one to 5% of some kind
of deleterious mutation. And so I think there's a question of like, how big is that market right
now that customers actually really want to find out? And then secondly, you know, is that price
point actually something that people actually want to tap into? So 23andMe, we've stayed in
the genotyping space, because we find it actually hits a broad number of our customer, like the
interest of what our customers are looking for, like customers want to know about things like
our type two diabetes report, or an Alzheimer's report, were very comprehensive on carrier status.
So we hit a broad amount of, you know, mutations that are more frequent in the population,
even the BRCA, you know, we, the BRCA mutations, which covers, you know, the common mutations in
the Ashkenazi population. So sequencing is definitely going to be more relevant for somebody
who has a family history of something where they really want to go and do an in depth analysis.
But in some ways, that's a very different experience than what 23andMe is trying to cultivate.
So on the health front, specifically now, because you you've been increasingly adding
more and more of these health reports as the FDA has been approving them, and one of them is
diabetes. So let's talk about the idea of this polygenic risk score. And how much do you see
that driving the business and just sales of DNA tests in the future, when especially when we've
seen a slowdown in the past year? Well, I think I think all the rage right now is the polygenic
risk scores is being able to say, I'm going to look at thousands of genetic mutations,
or millions of genetic mutations, and calculate a risk score about a certain disease. So we
launched one recently on on type two diabetes, where we look at, you know, hundreds of mutations,
and we say, this is the score for individuals, you know, roughly, you know, here's the 20% of
our customers who we say are genetically higher risk for type two diabetes. So it's definitely,
I think, the trend more and more where people are looking at the research side. And it goes back to
my first point in terms of scale. What's important that 23andMe has built is that we have 10 million
individuals, the consent rate is over 80%. We have this opportunity to make discoveries that we then
give back to our customers. And so we're looking at what are the next disease areas that we would
go and do research on, so that we could generate those reports back for customers. I think that
there has been a slowdown in the market. And I would say there's no one report that goes and like
people are buying for one specific type of report. People want an overall experience, and they want
fun, they want to discover about themselves, and they want some of the health side. So I think
there has been a market slowdown. And I think that there's potentially all kinds of reasons why and I
think I'd actually love to know like what your theories are on. I think it's I think a lot I
think people are wary of tech these days. So is it the Facebook effect that I think is trickling
over to you to healthcare? I mean I think it's hard to really know, but I would think that it's a
Facebook effect. That I think people are just more wary about what's going online and how is
the information being used. And I think that frankly all of the companies out there then we
have a responsibility to really work with our customers about like well how are you using our
information? And I look at like there's an interesting article in the New York Times today
even about some fertility apps that we're giving recommendations back. And you know it's
interesting like have those companies like is there actually a consent process? Is there a
research protocol? Like how are some of these companies actually using the information? And I
think it's really important that companies are transparent about it. And it's one of the things
I think has been a hallmark of 23andMe is that we've really tried from day one to be you know
transparent with our data security in terms of like breaches and how that we're protecting data
in that way as well as how we're honoring your privacy choices with you know with research. So
on the polygenic score specifically. So for a condition like diabetes which a lot of people
are at risk for it's very common type 2 diabetes. So how do you think about communicating levels of
risk back to your consumer base? Do you do you think about telling people that they're at lower
risk or is that an unsafe thing to communicate given that you know people's behavior could
change at any moment and and that that could change that you could become higher risk? So how
do you think about that when you're talking about such a common? I think we try to make sure that
we're like more and more I think the future of where we're going to go is being able to take
into consideration you know your diet, your exercise, your lifestyle, all these. And so your
score hopefully will evolve over time as you actually get more and more information that's
coming into it. So we want to give people that perspective is like listen you might be genetically
low risk for type 2 diabetes but the way you live puts you at higher risk. So I think that's the
future more and more of where everything is going to go is that you say you know the whole reason
why I always love genetics was because you get you get something that's fixed but then you have
this beautiful opportunity of changing with your environment. And so combining the the genetic risks
plus your environment will give you a really interesting perspective on how you're living
your life and what you are you really at risk for, what have you successfully you know successfully
managed those risks. You know we say in the company all the time you want to change what you can and
manage what you can't. And so you know change if you if I know I'm genetically higher risk for type
2 diabetes and I can change my diet and exercise like I can eventually have an impact on my outcomes.
You know there's certain conditions like BRCA like it's hard to you know that might be more
medically managed but we want to encourage our customers more and more to change what they can.
And what's what's been great is we have started to do these surveys of our customers about
how many of them are actually taking that next step. And we see that over 70 percent of our
customers are specifically changing their lifestyle based on the information that they've learned.
So they're trying to either change the diet and exercise. They're you know following up with
physicians but they're looking specifically to make change. So speaking of combining different
data sets I'd love to know when I can get genetic information on my phone because you know a lot of
people have a version of Apple Health where they can already incorporate their wearables information
their sleep and so on. So why not. We do. We have our app. OK. So we have the app. So you can download
the 23andMe app. You have the ability right now. We have partnerships with you know with Apple. We
are pulling in data right now with human API. So you know the challenge for customers and again it's
one of the things I push on for all entrepreneurs here is like customers want something interesting
back. So like I it's you know it's interesting to pull your medical record but like what are you going to like
just looking at your lab results is not terribly compelling. So like what is it that you can give people back. And so
that's where we're like we're spending a lot of time thinking about what is it with your genetic information. What
is the information that we can potentially pull and then what are some of those interesting insights we can actually
give you back. And so that's where we have an early version of something that we call action plan which is really
based on some of the information you've told us about you your genetic information and your age. And what are those
specific actions that you should be taking every year for your health. So to another part of your business which is
therapeutics I mean now 23andMe is increasingly valued as a therapeutics company. But we haven't seen anything much
from from the company publicly in terms of what are some of the early targets you're looking at. And can this thesis be
borne out around this idea that this database that you've collected right be potentially beneficial and moving you through
that process more quickly. So can you give us an update on just how that that therapeutics group is doing. The
therapeutics business should teach everyone patience because it's you know the reality of drug discovery is it takes a long
time. And you know we have we start from you know the the analysis the data and we look at all of these genetic variants. We
come up with hypotheses. We you know do it again a tremendous amount of follow up. So we have a number of programs in early
stage research and late stage research. We did a large collaboration last year with GSK. We have six six programs in
development now with GSK. We have a number that we've kept on our own. So it's exciting. Like I'm super excited about where it's
going. We haven't been terribly public about it in part because we understand like one it takes a long time. And to the reality of
drugs discovery is that there's a large number of failures. And so we want to set the expectations correctly when we know that we
have things that are going to move into humans. So we're hopeful that there'll be something moving into humans soon. But I'm
excited about the program. And I think that's again when I think about the mission of the company about helping people access
understand and benefit from the human genome. There's no better way to benefit from the human genome than to potentially have a
cure that's based on genetics. Well thank you. We're just about out of time. I really appreciate the discussion. I think our plan
was to do a selfie. Are we still doing that. Oh yeah.
Should we do one of the outage. Yeah we want one with the with everybody else. All right.
Thanks everybody.
